Cencora (0HF3.L) Bundle
From its 2001 formation through the merger of AmeriSource Health and Bergen Brunswig to its 2023 rebrand as Cencora, this pharmaceutical distribution powerhouse has grown through strategic moves-acquiring World Courier in 2012 to boost specialty logistics, buying MWI Veterinary Supply for $2.5 billion in 2015 to enter animal health, and expanding oncology capabilities with OneOncology in 2023-while playing a critical role in delivering remdesivir to hospitals during the COVID-19 crisis in 2020; today Cencora operates two main segments (U.S. and International Healthcare Solutions), employs over 46,000 people, leverages data analytics and specialty logistics to serve manufacturers and providers, and benefits from a strategic 15% stake held by Walgreens Boots Alliance (built in 2016 via a 22.7 million-share option), a market capitalization of about $66.5 billion and a stock price near $340.93 as of December 2025-all underpinning a business model that generates revenue from branded, generic and specialty drug distribution, value-added services, veterinary supply sales and premium logistics while pursuing a planned $1 billion investment through 2030 to expand its U.S. network.
AmerisourceBergen Corporation (0HF3.L): Intro
History- 2001 - AmeriSource Health Corporation and Bergen Brunswig Corporation merged to form AmerisourceBergen Corporation, creating one of the largest pharmaceutical distributors in the U.S.
- 2012 - Acquired World Courier (the largest specialty courier company globally), bolstering cold‑chain and specialty logistics capabilities.
- 2015 - Expanded into animal health by acquiring MWI Veterinary Supply for $2.5 billion, broadening product and service offerings.
- 2016 - Walgreens Boots Alliance increased its stake in AmerisourceBergen to ~15%, deepening a strategic distribution and commercial partnership.
- 2020 - Played a pivotal operational role in distributing remdesivir, the first COVID‑19 antiviral emergency treatment, to hospitals nationwide.
- 2023 - On August 30, AmerisourceBergen rebranded as Cencora to reflect its evolving global healthcare‑services strategy and identity.
- Mission focus: improve patient access to medications and services, optimize healthcare supply chains, and advance specialty and provider solutions.
- Strategic priorities: expand specialty distribution and clinical services, grow animal‑health offerings, and scale global logistics and patient‑support capabilities.
- See the company's stated direction and culture here: Mission Statement, Vision, & Core Values (2026) of AmerisourceBergen Corporation.
- Major strategic shareholder: Walgreens Boots Alliance (~15% stake, established 2016 as part of strategic alignment on retail and distribution initiatives).
- Other significant institutional owners typically include large asset managers (e.g., BlackRock, Vanguard, State Street) holding combined institutional percentages common for large-cap health distributors.
- Governance: public company with a board overseeing strategy, risk (including opioid litigation and supply‑chain risk), and executive leadership focused on services expansion and margin improvement.
- Core function: aggregate pharmaceutical manufacturers' supply, distribute drugs and related products to pharmacies, hospitals, long‑term care and other healthcare providers.
- Primary operating segments:
- Pharmaceutical distribution - high volume, low gross margin on wholesale drug distribution to retail and institutional customers.
- Specialty solutions - higher‑margin services for specialty and oncology drugs including hub services, patient support, and infusion logistics (linked with World Courier capabilities).
- Provider services - clinical services, revenue cycle management, and practice solutions for health systems and physicians.
- Animal health - distribution and services to veterinary practices via MWI Veterinary Supply.
- Supported by logistics (cold chain, global couriers), data analytics, manufacturer-commercial services, and patient‑support programs.
- Wholesale distribution margins: the largest revenue contributor in dollars (very high top-line volume) but relatively thin gross margins per unit.
- Specialty and services: higher margins and recurring revenue from clinical programs, specialty drug handling, hub services and provider solutions.
- Contracting and rebates: negotiated fees, manufacturer rebates and purchasing agreements add to profitability beyond transaction margins.
- Value‑added services: logistics premiums (expedited, cold chain), consulting, and data services increase per‑customer lifetime value.
| Metric (FY or notable period) | Figure |
|---|---|
| Annual Revenue (FY 2023, reported) | ~$214 billion |
| Net income (FY 2023, reported) | ~$1.6-1.8 billion |
| Total assets (FY 2023) | ~$65 billion |
| Major acquisition cost - MWI Veterinary Supply (2015) | $2.5 billion |
| Walgreens Boots Alliance stake (since 2016) | ~15% |
| Specialty logistics capability added (World Courier acquisition) | 2012; global cold‑chain & specialty courier network |
- Margin pressure in high‑volume distribution from pricing and reimbursement dynamics.
- Regulatory, legal and reputational risks (opioid litigation and compliance expectations in controlled substance distribution).
- Supply‑chain disruptions, cold‑chain complexity for specialty biologics, and dependency on large manufacturer contracts.
AmerisourceBergen Corporation (0HF3.L): History
AmerisourceBergen Corporation (0HF3.L) traces its origins to the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation and, after decades of growth through distribution scale and services, rebranded as Cencora in 2023 while retaining the AmerisourceBergen legacy. The company's evolution has been driven by consolidation in pharmaceutical distribution, specialty services expansion, and strategic partnerships with major pharmacy and health-system players.- Largest shareholder (Aug 2023): Walgreens Boots Alliance - 15% stake.
- 2016 transaction: Walgreens exercised an option to buy 22.7 million shares, lifting ownership to 15%.
- Public float: ~85% of shares publicly traded across institutional and retail investors.
- Ticker and listing: Listed on the New York Stock Exchange under the ticker symbol 'COR' after the 2023 rebrand.
- Market capitalization (Dec 2025): approximately $66.5 billion.
| Metric | Value |
|---|---|
| Largest shareholder | Walgreens Boots Alliance (15%, Aug 2023) |
| Shares acquired by WBA (2016) | 22.7 million shares |
| Publicly traded share percentage | ~85% |
| NYSE ticker (post-2023) | COR |
| Market capitalization (Dec 2025) | ~$66.5 billion |
- Ownership impact: The Walgreens stake provides strategic alignment for pharmacy distribution and retail partnership opportunities, while the broad public float supplies capital access and governance diversification.
- Investor base: Institutional investors, mutual funds, and retail shareholders collectively hold the ~85% public portion, supporting liquidity and market signaling for strategic initiatives.
AmerisourceBergen Corporation (0HF3.L): Ownership Structure
AmerisourceBergen Corporation (0HF3.L), operating under the Cencora enterprise identity, is a global pharmaceutical sourcing and distribution leader focused on connecting manufacturers, healthcare providers and patients. Its strategic position in the specialty distribution, pharmaceutical services and consulting markets drives scale, margin capture and steady cash flow.
- Publicly listed entity with institutional investors holding the majority of shares.
- Large passive index funds and mutual funds (e.g., Vanguard, BlackRock) are among top shareholders.
- Insider ownership is modest; executive and board holdings align partially through long-term incentive plans.
- Corporate governance structured for audited supply-chain controls and compliance with U.S. and global pharmaceutical regulations.
Mission and values (as stated under the Cencora identity):
- Cencora's mission is to create healthier futures by advancing the development and delivery of pharmaceuticals and healthcare products.
- The company is committed to fostering a positive impact on global health by improving access to essential medications and healthcare services.
- Cencora values innovation, efficiency, and reliability, striving to enhance patient care through its comprehensive distribution and service offerings.
- The organization emphasizes collaboration with pharmaceutical innovators to facilitate market access to therapies, ensuring timely delivery to healthcare providers.
- Cencora upholds a strong ethical framework, focusing on the safety and security of the pharmaceutical supply chain to protect patients and communities.
- The company's values are reflected in its diverse workforce, with over 46,000 team members worldwide dedicated to its mission.
How AmerisourceBergen / Cencora works and makes money:
- Pharmaceutical distribution - buys in bulk from manufacturers and sells to hospitals, pharmacies and clinics, capturing gross margin on volume-driven logistics.
- Specialty drug services - provides access, reimbursement support, patient services and hub services for high-cost biologics and specialty therapies.
- Manufacturer services - consulting, commercialization support, packaging, and direct-to-provider supply-chain solutions that create fee-based revenue streams.
- Global sourcing and logistics - contract logistics, cold-chain capabilities and fulfillment services that support recurring contractual revenue.
| Metric | Most recent reported (approx.) |
|---|---|
| Annual Revenue | ~$238.6 billion |
| Net Income | ~$1.7 billion |
| Market Capitalization | ~$18 billion |
| Employees | ~46,000+ |
| Primary Segments | Distribution, Specialty Solutions, Manufacturer Services |
Key financial and operational levers:
- Scale-driven purchasing and logistics efficiency reduce per-unit costs and protect margins on high-volume distribution.
- Higher-margin specialty services (access, reimbursement, patient support) improve blended profitability.
- Long-term contracts with health systems and manufacturers stabilize revenue visibility and free cash flow generation.
- Investment in technology and cold-chain capabilities supports growth in biologics and personalized therapies.
Further reading: AmerisourceBergen Corporation: History, Ownership, Mission, How It Works & Makes Money
AmerisourceBergen Corporation (0HF3.L): Mission and Values
AmerisourceBergen Corporation (0HF3.L) operates as a global pharmaceutical sourcing and distribution company with integrated services spanning logistics, commercialization, analytics, and specialty distribution. The business model focuses on ensuring a secure, efficient supply chain for pharmaceuticals and related healthcare products while offering services that improve provider and manufacturer outcomes.- Two primary reporting segments: U.S. Healthcare Solutions and International Healthcare Solutions, each tailored to different markets and customer needs.
- U.S. Healthcare Solutions: broad distribution of branded and generic pharmaceuticals, over-the-counter products, vaccines, and home healthcare supplies to hospitals, independent pharmacies, long-term care facilities, and clinicians.
- International Healthcare Solutions: pharmaceutical wholesale, global commercialization services, specialty distribution and market access support across international markets.
- End-to-end distribution network linking manufacturers to providers and patients via national distribution centers, last-mile logistics, and pharmacy services.
- Specialty logistics and clinical trial sample transportation enhanced by the 2012 acquisition of World Courier, enabling cold-chain, temperature-controlled global distribution for biologics and specialty therapies.
- Data analytics, outcomes research, and consulting services that provide real-world evidence, supply optimization, and value-based contracting support to payers, providers, and manufacturers.
- Integrated supply-chain controls and compliance systems to manage recalls, track serializations, and ensure regulatory adherence across jurisdictions.
| Metric | Value (FY 2023, approx.) |
|---|---|
| Revenue | $238.6 billion |
| Net income | $1.7 billion |
| Operating income | $2.6 billion |
| Total assets | $51.0 billion |
| Employees (global) | ~42,000 |
- Wholesale distribution margins on high-volume pharmaceutical flows (contract manufacturing purchase and resale relationships with tight volume-based pricing).
- Specialty and oncology distribution, including gross margin on high-cost specialty drugs and associated specialty pharmacy services and support programs.
- Logistics and clinical trial services revenue from World Courier-derived capabilities, including premium pricing for cold-chain and time-sensitive shipments.
- Commercialization services and contract sales/marketing for manufacturers entering international markets (market access, regulatory support, and launch services).
- Analytics, consulting, and outcomes research fees and value-based contracting arrangements that tie payment to clinical outcomes.
- Extensive DC footprint and inventory management systems that reduce stockouts and expedite order fulfillment to thousands of healthcare locations daily.
- Robust cold-chain and specialty logistics supporting biologics and cell-and-gene therapies-critical for manufacturers and academic clinical sites.
- Data platforms that aggregate claims, dispensing, and clinical data to support formulary decisions, utilization management, and population health interventions.
- Acquisition of World Courier (completed 2012) expanded global specialty logistics and sample management capabilities-central to supporting clinical trials and biologic distribution.
- Ongoing investments in digital supply-chain visibility, serialization, and analytics to meet regulatory requirements and to enable more efficient manufacturer-provider collaborations.
AmerisourceBergen Corporation (0HF3.L): How It Works
AmerisourceBergen Corporation (0HF3.L) operates as a global healthcare solutions company that generates revenue primarily through distribution of pharmaceuticals, specialty logistics and services, and ancillary healthcare offerings. Its business model combines high-volume national distribution with higher-margin specialty services, analytics, and clinical support, enabling scale-driven margin capture across the pharmaceutical supply chain.- Core distribution: nationwide and international wholesale distribution of brand-name, specialty and generic medications to hospitals, pharmacies, physician offices and long-term care facilities.
- Retail and consumer products: distribution of over-the-counter (OTC) healthcare items and home healthcare supplies for retail and institutional customers.
- Specialty services: specialty pharmacy, infusion services, patient support programs, hub services and clinical logistics for biopharmaceuticals (including World Courier's cold-chain logistics).
- Veterinary and animal health: revenues from MWI Veterinary Supply (acquired 2015), supplying veterinary practices and animal health channels.
- Data & consulting: value-added services for manufacturers and providers-data analytics, outcomes research, reimbursement and consulting services that tie product distribution to clinical and commercial outcomes.
- Volume-based distribution margins: purchasing large volumes from manufacturers, earning small per-unit margins on high-turnover prescription and OTC products.
- Specialty and clinical services margin uplift: higher gross margins from specialty pharmacy services, patient support programs and infusion services where care coordination and clinical management create premium pricing.
- Logistics and premium handling fees: temperature-controlled transport, clinical trial logistics and secure handling via World Courier command higher fees per shipment.
- Contract and service revenue: long-term contracts with health systems, retailers and manufacturers for consulting, analytics and managed services produce recurring fee income.
- Segment diversification (animal health, specialty, distribution) reduces reliance on any single revenue source and captures cross-selling opportunities.
| Metric | FY2021 | FY2022 | FY2023 (approx.) |
|---|---|---|---|
| Revenue | $189.9 billion | $214.1 billion | $240.4 billion |
| Net income (GAAP) | $1.5 billion | $1.8 billion | $2.1 billion |
| Gross margin | ~5.3% | ~5.4% | ~5.5% |
| Adjusted EBITDA | $3.2 billion | $3.4 billion | $3.7 billion |
| Employees | ~33,000 | ~38,000 | ~40,000 |
- Pharmaceutical distribution: ~89% of total revenue - high-volume, low-margin
- Specialty and solutions (including specialty pharmacy, clinical services, logistics): ~8-9% - higher-margin growth area
- Animal health / MWI Veterinary Supply: ~2-3% - steadier margin contribution
- MWI Veterinary Supply (2015 acquisition): established a meaningful footprint in the animal health market, adding veterinary product distribution and services revenue and cross-selling opportunities.
- World Courier and specialty logistics: premium cold-chain and clinical trial logistics capture higher per-shipment fees for biologics and cell/gene therapies, supporting growing biopharma demand.
- Value-added services expansion: investments in data analytics, outcomes research and consulting increase stickiness with manufacturers and payors and create fee-for-service revenue streams beyond pure distribution.
- Strategic partnerships and ownership moves: partnerships and stake changes-such as the increased engagement by Walgreens Boots Alliance in past years-have expanded retail channel collaborations and improved negotiated supply arrangements and scale economics.
- Procurement & vendor terms: leverage over manufacturers to secure purchase rebates, prompt-pay discounts and national contracts that underpin narrow but consistent distribution margins.
- Inventory & logistics optimization: scale enables low per-unit logistics cost; specialty cold-chain and expedited logistics carry premium fees that lift overall margin profile.
- Service bundling: combining distribution with specialty pharmacy, patient support and analytics increases lifetime value per customer and reduces churn.
- Contract pricing & pass-through costs: much revenue is contracted and indexed to volumes/ASP; pass-through of drug cost movements can inflate revenue while margins remain stable.
| KPI | Example FY2023 Value (approx.) |
|---|---|
| Total revenue | $240.4 billion |
| Specialty & solutions revenue | $19-22 billion |
| Animal health revenue (MWI) | $5-7 billion |
| Gross margin % | ~5.5% |
| Adjusted EBITDA | $3.7 billion |
AmerisourceBergen Corporation (0HF3.L): How It Makes Money
AmerisourceBergen generates cash flow by acting as a high-volume distributor, logistics partner and services provider across pharmaceuticals, specialty therapies and provider-solution lines. Its business model combines low-margin, high-volume commodity distribution with higher-margin specialty services, clinical support and channel management.- Core distribution: national and global distribution of branded and generic drugs to retail pharmacies, hospitals and health systems.
- Specialty pharmacy & services: coordination, patient support and fulfillment for oncology, rare disease and specialty biologics.
- Manufacturer services: commercialization, contract logistics, cold-chain management and hub services for pharma companies.
- Clinical & professional services: oncology network (via OneOncology), infusion services and site-of-care solutions.
| Metric | Value / Note |
|---|---|
| Market price (Dec 2025) | $340.93 per share |
| Market capitalization (Dec 2025) | ~$66.5 billion |
| Planned capital deployment | $1.0 billion investment in U.S. distribution network by 2030 |
| Strategic acquisition | OneOncology (2023) - expanded oncology services & patient access |
| Revenue model split (approx.) | Distribution & supply chain ~75%; Specialty & services ~20%; Other solutions ~5% |
| Recent revenue (approx. FY) | $218.2 billion (illustrative, major portion from distribution) |
| Analyst sentiment | FY2025 adjusted EPS estimates revised upward - consensus expects continued earnings growth |
- Scale economics: tight inventory turns and negotiated manufacturer rebates drive thin but steady distribution margins.
- Specialty mix: growth in high-cost specialty drugs increases average selling price per script and boosts services margins.
- Value-added services: logistics, cold-chain and clinical programs command higher margins and recurring fee models.
- Network investments: the $1B expansion aims to shorten lead times, reduce logistics costs and support specialty drug handling.
- Leading global position with market cap ~ $66.5B and a strong stock-price performance (Dec 2025: $340.93), reflecting investor confidence.
- OneOncology acquisition (2023) strengthened oncology capabilities and provider relationships, feeding specialty growth.
- Analysts have raised FY2025 adjusted EPS targets, consistent with a strategy focused on specialty drugs and international expansion.
- Planned investments and service diversification position the company to capture higher-margin specialty demand and logistics work.
Cencora (0HF3.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.